If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,072.00    106.00 (5.39%)
Bid:
2,058.00
Ask:
2,072.00
Spread: 14.00 (0.68%)
Market Cap: £1.38b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Pre-Close Trading Statement

4 Jul 2012 07:00

RNS Number : 8517G
Genus PLC
04 July 2012
 



For Immediate Release 4 July 2012

 

Genus plc

('Genus' or the 'Group')

 

Pre-Close Trading Statement

'On track to deliver market expectations'

 

Genus, a leading global animal genetics company, today provides the following update on trading for its financial year ended 30 June 2012.

 

Trading

 

Genus has continued to perform well in the final two months of the financial year since the Interim Management Statement (IMS) issued on 3 May 2012. As a result, the Group expects to report a good performance for the year to 30 June 2012 with adjusted profit before tax in line with market expectations.

 

In the year to 30 June 2012, revenue has continued to grow both in porcine and bovine with particularly strong growth in Latin America and Asia. Whilst there has been a modest tightening of margins for some of Genus' customers towards the end of the year, market conditions and customer demand have remained good in most markets although some softness has been experienced in bovine in North America.

 

With pricing generally firm, adjusted operating profit has improved in line with expectations despite increasing investment in research and development and in strengthening management teams across the Group to support future growth. Profits have improved strongly in Asia, particularly in Russia and China, and in Latin America. The Group's businesses in North America have also performed well with improved royalty income driving growth in porcine and good pricing discipline and cost control in bovine more than offsetting the softness in that market. Europe has performed broadly in line with the prior year.

 

As indicated in the Group's IMS on 3 May 2012, a new strategy, designed to achieve an improving rate of growth from 2014 onwards, has been developed centred around four key elements; improved product differentiation, targeting key markets and segments, tailoring the business model and strengthening core competencies. The strategy envisages strong growth in emerging markets, particularly in China, where discussions with potential new customers in relation to porcine joint ventures are progressing well.

 

Exceptional items

 

The Group is expecting to report a net exceptional credit in the order of up to £5m before tax in the year to 30 June 2012. This comprises three elements:

 

(1) A restructuring charge principally relating to refocusing the porcine business in Europe on larger integrated customers. As indicated in the IMS on 3 May 2012, we expect the cost of the restructuring to be up to £2m, approximately half of which is non-cash.

 

(2) A provision for potential pension costs in respect of the multi-employer Milk Pension Fund (MPF). As indicated in Note 34 to Genus' financial statements for the year ended June 2011, Genus is joint and severally liable for the obligations of the MPF.The provision relates to potential future cash payments that may arise over a number of years as a result of the possibility of certain employers in the MPF being unable to meet increased deficit repair contributions that would normally be expected to be payable to the fund. The expected provision is in the order of £20m.

 

(3) An exceptional credit as a result of a reassessment of the carrying value of the Group's porcine pure line breeding animals under IAS 41. The credit is estimated to be approximately £25m.

 

Further details on the pension provision (item 2 above) and the exceptional credit (items 3 above) are given in the appendix.

 

Genus will announce its preliminary results for the year to 30 June 2012 on 4 September 2012.

 

For further information please contact:-

 

Genus plc: Tel: 01256 345970

 

Karim Bitar, Chief Executive

John Worby, Finance Director

 

Buchanan: Tel: 0207 466 5000

 

Charles Ryland

 

This announcement is available on the Genus website, www.genusplc.com

 

 

Appendix

 

Valuation of Porcine Biological Assets

 

Following a review of its accounting for biological assets under IAS41, Genus has concluded that it should change the basis of valuation of its pure line breeding animals to represent more fairly the likely market value of these animals. Pure line breeding animals are those animals retained by Genus and represent the repository of the elite genetics. As there is no active market for these pure line breeding animals, in previous years they were valued using the fair value of great grand-parent animals since these represented the nearest biological asset for which there was an active market. As the direct sale of the great grand-parent animals has reduced with increased use of the royalty model, Genus has reviewed the basis of valuation and concluded it would be more appropriate to value these animals as a genetic nucleus herd using discounted cash flow techniques.

 

The impact of this revision in the valuation method of the pure line breeding animals is expected to increase the carrying value of porcine assets at 30 June 2012 by approximately £25m. This increase in valuation has no impact on the Group's cash flow but will be recorded as an exceptional credit in Genus' financial statements for the year ended 30 June 2012.

 

Pension Provision

As indicated in Note 34 to Genus' financial statements for the year ended June 2011, Genus is a participating employer of the Milk Pension Fund (MPF), and together with other participating employers, is joint and severally liable for the scheme's obligations. In normal circumstances, Genus only accounts for its section and its share of any orphan assets and liabilities. At 30 June 2011, its share represented approx 37% of the Milk Pension Scheme obligations and as a result, the Group's liability for defined benefit obligations at 30 June 2011 calculated under IAS 19 was £23.6m.

 

The tri-annual valuation of the MPF at March 2012 is expected to show an increased deficit particularly following recent reductions in gilt yields. In the light of this, and the likely difficulty certain other employers may experience in fulfilling their normal obligations to the scheme, the Group has concluded that it will be necessary to make a provision in its financial statements for the year to 30 June 2012. The provision, which will be shown as an exceptional item, will be based on its estimate of the additional amounts it may have to pay to the MPF over a number of years under its joint and several liability obligations. The Group currently estimates that the provision will be in the region of £20m. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBKNDQFBKDQOK
Date   Source Headline
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSInterim Results
26th Feb 20257:00 amRNSNon-Executive Director Retirement
3rd Feb 20253:17 pmRNSBlock Listing Six Monthly Return
3rd Feb 20259:40 amRNSTotal Voting Rights
15th Jan 20257:00 amRNSHalf Year Trading Update – Ahead of expectations
12th Dec 20245:07 pmRNSNotification of Major Holdings
20th Nov 20243:32 pmRNSResults of AGM
20th Nov 20247:00 amRNSAGM Trading Update
1st Nov 202410:42 amRNSTotal Voting Rights
22nd Oct 20247:00 amRNSChief Financial Officer Retirement
14th Oct 20247:00 amRNSAnnual Report and Annual General Meeting
18th Sep 202411:17 amRNSDirector/PDMR Shareholding
16th Sep 20244:29 pmRNSDirector/PDMR Shareholding
12th Sep 20244:51 pmRNSDirector/PDMR Shareholding
12th Sep 20247:00 amRNSDirector/PDMR Shareholding
9th Sep 20247:00 amRNSDirector/PDMR Shareholding
6th Sep 202412:31 pmRNSDirector/PDMR Shareholding
6th Sep 202412:30 pmRNSDirector/PDMR Shareholding
5th Sep 20247:00 amRNSPreliminary Results
1st Aug 20244:26 pmRNSBlock Listing Six Monthly Return
1st Aug 20243:38 pmRNSTotal Voting Rights
17th Jul 20247:00 amRNSTrading Update
3rd Jun 202410:48 amRNSHolding(s) in Company
1st May 20241:59 pmRNSTotal Voting Rights
22nd Feb 20247:00 amRNSInterim Results
15th Feb 20247:00 amRNSTrading Update
1st Feb 20244:24 pmRNSBlock listing Interim Review
1st Feb 20244:21 pmRNSTotal Voting Rights
12th Dec 20237:00 amRNSNon-Executive Director Appointment
22nd Nov 20231:08 pmRNSResult of AGM
22nd Nov 20237:00 amRNSAGM Trading Update
1st Nov 20234:46 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSCapital Markets Event
13th Oct 20237:00 amRNSAnnual Report and Annual General Meeting
5th Oct 202310:19 amRNSPos. determination-PRRS resistant pigs-Colombia
2nd Oct 202311:12 amRNSTotal Voting Rights
15th Sep 20231:07 pmRNSDirector/PDMR Shareholding
15th Sep 202310:04 amRNSDirector/PDMR Shareholding
7th Sep 20237:00 amRNSPreliminary Results
25th Aug 20238:35 amRNSNotification of Major Holdings
23rd Aug 20239:25 amRNSDirectorate Change
1st Aug 202311:41 amRNSBlock listing Interim Review
1st Aug 202311:36 amRNSTotal Voting Rights
3rd Jul 202311:02 amRNSTotal Voting Rights
16th Jun 20235:33 pmRNSNational Milk Records plc - Form 8.3
16th Jun 20235:10 pmRNSForm 8.3 (OPD) - National Milk Records plc
8th Jun 20233:51 pmRNSDirector/PDMR Shareholding
7th Jun 20235:11 pmRNSNotification of Major Holdings
7th Jun 20235:08 pmRNSNotification of Major Holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.